Partnership Intends to Accelerate Translation of Discoveries into
Novel Therapies for Patients
WILMINGTON, Mass.--(BUSINESS WIRE)--Sep. 22, 2016--
Charles River Laboratories International, Inc. (NYSE: CRL) today
announced that it has entered into a strategic partnership agreement
with The Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI),
intended to accelerate the development of therapeutics that arise from
discoveries made in Tri-I TDI’s academic labs.
Tri-I TDI is a cooperative endeavor of Memorial Sloan Kettering Cancer
Center, The Rockefeller University, and Weill Cornell Medicine, with a
focus on the early stages of compound and biologic agent development, as
well as “proof of concept” studies that determine which drug candidates
can successfully alter the course of a disease.
“This partnership reinforces Charles River’s continued commitment to
expedite the early-stage development of innovative treatments and
therapies for patients,” said Dr. Emily Hickey, Corporate Senior Vice
President, Global Discovery Services, Charles River. “Our new
partnership will leverage Charles River’s drug discovery and safety
assessment expertise with both Tri-I TDI’s research strengths and the
cutting-edge work of their member institutions’ scientific leaders.”
Through this partnership, Charles River will provide Tri-I TDI with
discovery and safety assessment services to support a range of projects
that are at the frontier of science. The collaboration will enhance
Tri-I TDI’s efforts to more effectively develop therapeutics for unmet
“Our partnership with Charles River opens up a new pathway to innovation
for Tri-I TDI,” said Michael A. Foley, Chief Executive Officer, Tri-I
TDI. “Its decades of experience in drug discovery and safety assessment,
combined with a robust portfolio of services, will provide us with
additional capabilities to rapidly advance our projects.”
About The Tri-Institutional Therapeutics Discovery Institute
The Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI).
Tri-I TDI is a partnership of three world-renowned scientific and
medical institutions — Memorial Sloan Kettering Cancer Center, The
Rockefeller University and Weill Cornell Medicine. A novel partnership
of academic institutions, the Tri-I TDI links researchers in basic and
clinical science with experts in drug discovery from the biotech and
pharmaceutical industries, with the goal of more efficiently translating
discoveries into therapies for disease. Launched in 2013 in New York
City the Tri-I TDI focuses on the early stages of developing compounds
and biologic agents, and conducts “proof of concept” studies needed to
demonstrate that drug candidates can successfully alter the course of a
disease. To learn more, visit www.tritdi.org.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their research
and drug development efforts. Our dedicated employees are focused on
providing clients with exactly what they need to improve and expedite
the discovery, early-stage development and safe manufacture of new
therapies for the patients who need them. To learn more about our unique
portfolio and breadth of services, visit www.criver.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160922005165/en/
Source: Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc.
E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
Amy Cianciaruso, 781-222-6168
President, Public Relations